BridgeBio Pharma, Inc. (BBIO) Stock Forecast
BBIO analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.57 / 5 from 23 analysts
- Price target
- $108.27 average of analyst targets
- Upside to target
- +63.1% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.63
- 52-week range
- $53.24 – $90.17
BBIO analyst ratings
23 analystsNumber of analysts at each rating.
BBIO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BBIO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.58 | −$0.66 | −$0.40 | −$0.72 | +19.6% | 7 |
| Current fiscal year (2026) | −$2.60 | −$3.01 | −$1.88 | −$3.78 | +31.3% | 8 |
| Next fiscal year (2027) | −$0.26 | −$2.42 | $1.31 | −$2.60 | +90.2% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BBIO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $282.7M | $253.5M | $347.4M | +134.2% | 18 |
| Current fiscal year (2026) | $1.03B | $965.0M | $1.12B | +106.0% | 20 |
| Next fiscal year (2027) | $1.70B | $1.48B | $1.97B | +64.0% | 19 |
BBIO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BBIO revenue: reported and forecast
BBIO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.45 | −$0.67 | −$0.63 | −$0.63 | −$0.58 | +27.2% | 1 up · 0 down |
| Current fiscal year (2026) | −$2.15 | −$2.68 | −$2.58 | −$2.58 | −$2.60 | +20.8% | 0 up · 8 down |
| Next fiscal year (2027) | $0.59 | $0.15 | $0.03 | $0.03 | −$0.26 | −143.3% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BBIO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BBIO beat in 3 of 12.
What analysts expect from BBIO
23 analysts cover BridgeBio Pharma; their consensus rating is strong buy (4.57 on a 1–5 scale, where 5 is a strong buy). The average price target is $108.27, 63.1% above the latest close of $66.39. Analysts expect earnings of −$2.60 per share for 2026, +31.3% from a year earlier. For 2027 the average estimate is −$0.26 per share on revenue of $1.7 billion. BridgeBio Pharma beat the EPS estimate in 3 of the last 12 quarters.
Related: BBIO income statement, BBIO key metrics, BBIO chart. See the BBIO stock overview for the latest quote and news.
BBIO forecast FAQ
What is BridgeBio Pharma's price target?
The average analyst price target for BridgeBio Pharma is $108.27, 63.1% above the latest close of $66.39.
Is BridgeBio Pharma a buy, hold or sell?
Of 23 analysts covering BridgeBio Pharma, 15 rate it a strong buy, 6 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is BridgeBio Pharma's EPS forecast?
Analysts forecast −$2.60 per share for 2026 (range −$3.01 to −$1.88); for 2027 the estimate is −$0.26.
What is BridgeBio Pharma's revenue forecast?
The average revenue estimate for 2026 is $1.0 billion, growth of 106.0%; for 2027 it is $1.7 billion.
When does BridgeBio Pharma report earnings?
BridgeBio Pharma is expected to report results for the quarter ending September 30, 2026 on November 4, 2026; the EPS estimate is $-0.63.
Does BridgeBio Pharma usually beat earnings estimates?
BridgeBio Pharma reported EPS at or above the analyst estimate in 3 of the last 12 quarters.